Did You Know...
...that Charles Goodyear performed some of his experiments on rubber while in debtor's prison? He was there so often he referred to it as his "hotel". Chronically in debt because of poor business sense and ill health, Goodyear depended on the generosity of friends and family. Even after he unlocked the secret to vulcanizing rubber, he was unable to improve his financial situation. When he died, his estate was $200,000 in debt.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8163296 | Dimensional analysis of saccharide conjugates with GPC and SEC-MALS GPC (gel permeation chromatography) and size exclusion chromatography with detection by multi-angle light scattering photometry (SEC-MALS) can be used to accurately measure molecular size and molar mass, respectively, of saccharide conjugates. The invention provides... | 04/24/2012 |
| 8137680 | Analysis of saccharide vaccines without interference The invention is based on methods that allow analysis of mixed meningococcal saccharides from multiple serogroups even though they share monosaccharide units. With a combination of saccharides from serogroups C, W135 and Y, the invention analyses sialic acid, glucos... | 03/20/2012 |
| 8128942 | Anti-sepsis conjugate vaccine The present invention provides an immunogenic conjugate comprising biologically deacylated gram-negative bacterial moieties linked to D. discoideum proteinase 1, as well as novel subunits thereof, and methods of making and using the conjugates in vaccines to ... | 03/06/2012 |
| 8101194 | Immunogenic compositions for the prevention and treatment of meningococcal disease The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that imm... | 01/24/2012 |
| 8097260 | Lipid a deficient mutants of The invention provides lipid A deficient mutant Neisseria meningitidis cells, pharmaceutical compositions incorporating such cells, and methods of using such cells. ... | 01/17/2012 |
| 8039007 | Polypeptides from Various specific meningococcal proteins are disclosed. The invention provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by meningococcus, such as bacteria... | 10/18/2011 |
| 8034358 | Surface antigen The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are al... | 10/11/2011 |
| 7947291 | Modified surface antigen Novel proteins that constitute modified forms of a Neisseria meningitidis surface antigen and encoding nucleic acids are provided. The modified surface proteins are characterized by having deletions of non-conserved amino acids, and thereby being capable of e... | 05/24/2011 |
| 7923018 | Vaccine The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine comprising one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and t... | 04/12/2011 |
| 7910117 | Vaccine The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and tr... | 03/22/2011 |
| 7862827 | Combination neisserial compositions Compositions comprising a first biological molecule from a Neisseria bacterium and a second biological molecule from a Neisseria bacterium. The term “biological molecule” includes proteins and nucleic acids. Preferred Neisseria species are | 01/04/2011 |
| 7838015 | Adjuvanted meningococcus compositions A combination of CpG oligonucleotides and polymer microparticles is an extremely effective adjuvant for Neisserial antigens. The invention therefore provides a composition comprising: (a) a Neisserial antigen; (b) a CpG oligonucleotide; and (c) a biodegradable polym... | 11/23/2010 |
| 7803387 | Heterologous expression of Neisserial proteins Alternative and improved approaches to the heterologous expression of the proteins of Neisseria meningitidis and Neisseria gonorrhoeae. These approaches typically affect the level of expression, the ease of purification, the cellular localization, and/... | 09/28/2010 |
| 7794733 | Omp85 proteins of and , compositions containing same and methods of use thereof Nucleic acid and amino acid sequences of the Omp85 proteins of N. gonorrhoeae and N. meningitidis, and fragments thereof are useful in vaccine compositions, therapeutic compositions and diagnostic compositions for use in the prevention, treatment and d... | 09/14/2010 |
| 7704513 | Nucleic acids and polypeptides specific for pathogenic strains of the genus The invention concerns nucleic acids coding for polypeptides specific of the Neisseria genus pathogenic strains, the corresponding polypeptides, and their diagnostic and therapeutic applications. ... | 04/27/2010 |
| 7700119 | 85kDa neisserial antigen An 85 kDa antigen from Neisseria meningitidis and Neisseria gonorrhoeae has been cloned, sequenced and expressed. The antigen is common to diverse strains, serogroups and serotypes of N. meningitidis, and also to N. gonorrhoeae, N. polysaccha... | 04/20/2010 |
| 7662399 | BASB054 polypeptides The invention provides BASB047, BASB054, BASB068 and BASB069 polypeptides, and polynucleotides encoding BASB047, BASB054, BASB068 and BASB069 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylact... | 02/16/2010 |
| 7655245 | Neisserial antigens The invention provides proteins from Neisseria meningitidis (strains A & B) and from Neisseria gonorrhoeae, including amino acid sequences, the corresponding nucleotide sequences, expression data, and serological data. The proteins are useful antigens ... | 02/02/2010 |
| 7604810 | Conserved Neisserial antigens To ensure maximum cross-strain recognition and reactivity, regions of proteins that are conserved between different Neisserial species, serogroups and strains can be used. The invention provides proteins which comprise stretches of amino acid sequence that are share... | 10/20/2009 |
| 7585510 | Vaccine The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and tr... | 09/08/2009 |
| 7534444 | Molecular mimetics of meningococcal B epitopes which elicit functionally active antibodies Molecular mimetics of a surface-exposed epitope on loop 4 of PorA of Neisseria meningitidis serogroup B (MenB) P1.2 serosubtype and antibodies produced against the same are disclosed. Compositions containing such molecular mimetics or the antibodies thereto c... | 05/19/2009 |
| 7438918 | Lipid A deficient mutants of The invention provides lipid A deficient mutant Neisseria meningitidis cells, pharmaceutical compositions incorporating such cells, and methods of using such cells. ... | 10/21/2008 |
| 7422754 | compounds and anti-infection applications thereof The invention provides novel Neisseria meningitides (Nm) polypeptides and polynucleotides which cover the Nm genetic diversity, and which correspond to polypeptide of Nm outer membrane and/or periplasma, and to methods for producing such Nm compounds. Also pr... | 09/09/2008 |
| 7384768 | Nucleic acids and polypeptides specific for pathogenic strains of the genus The invention concerns nucleic acids coding for polypeptides specific of the Neisseria genus pathogenic strains, the corresponding polypeptides, and their diagnostic and therapeutic applications. ... | 06/10/2008 |
| 7384645 | Outer membrane vesicles from gram negative bacteria and use as a vaccine A composition is prepared from a mixture of different vesicles, such as outer membrane vesicles (OMVs) and vaccines are based thereon. Another composition comprises in a single vesicle a combination of antigens and/or other vesicle components deriving from separate ... | 06/10/2008 |
| 7368261 | Conserved antigens To ensure maximum cross-strain recognition and reactivity, regions of proteins that are conserved between different Neisserial species, serogroups and strains can be used. The invention provides proteins which comprise stretches of amino acid sequence that are share... | 05/06/2008 |
| 7368556 | DNA and proteins or peptides specific of bacteria of the species, methods for obtaining them and biological applications thereof The DNA of the invention are characterised in that they concern the whole or part of genes, with their reading frame, to be found in Neisseria meningitidis, but not in Neisseria gonorrhoeae, or in Neisseria lactamica except the genes involved in... | 05/06/2008 |
| 7320958 | Coleopteran-toxic polypeptide compositions Disclosed are novel insecticidal polypeptides, and compositions comprising these polypeptides, peptide fragments thereof, and antibodies specific therefor. Also disclosed are vectors, transformed host cells, and transgenic plants that contain nucleic acid segments t... | 01/22/2008 |
| 7285281 | Mutant forms of cholera holotoxin as an adjuvant Mutant cholera holotoxins comprising a cholera toxin subunit A having single amino acid substitutions in the amino acid positions 16 or 72 or a double amino acid substitution in the amino acid positions 16 and 68 or 68 and 72 have reduced toxicity compared to the wi... | 10/23/2007 |
| 7273611 | Proteinase K resistant surface protein of neisseria meningitidis The identification of a highly conserved, immunologically accessible antigen on the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to proteinase K and has an apparent molec... | 09/25/2007 |
| 7255867 | Vaccine Effective stimulation of immune responses is achieved through the use of a group A streptococcal antigen combined with proteosome adjuvant. The compositions are provided in particular for intranasal administration. The vaccine compositions are provided for use in in... | 08/14/2007 |
| 7241867 | Polypeptide encoded by a nucleotide sequence of a nontypeable strain of genome The invention relates to the polynucleotide sequence of a nontypeable stain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response... | 07/10/2007 |
| 7238345 | Recombinant microorganism expressing meningococcal class 1 outer membrane protein Outer-membrane vesicles, Class 1 outer membrane proteins of Neisseria meningitidis, fragments or oligopeptides containing epitopes of the Class I OMP can be used to immunize against meningococcal disease. ... | 07/03/2007 |
| 7235242 | IgA1 protease fragment as carrier peptides The present invention is concerned with a fragment of IgA1-protease having 40 to 200 amino acid residues and comprising at least 40 amino acids of an amino acid sequence as shown in SEQ ID NO:1, beginning with the amino acid in any one of positions 1 to 5 and ending... | 06/26/2007 |
| 7169392 | serogroup B glycoconjugates and methods of producing the same The present invention pertains generally to novel Neisseria meningitidis serogroup B glycoconjugates. More particularly, the invention pertains to glycoconjugates formed from a Neisseria meningitidis serogroup B capsular oligosaccharide derivative (Men... | 01/30/2007 |
| 7163926 | Adjuvant-containing vaccines This invention provides a DNA vaccine which comprises a naked DNA incorporating and expressing in vivo a nucleotide sequence encoding an antigenic polypeptide, preferably a gene of a pathogenic agent, and at least one adjuvant compound chosen from the polymers of ac... | 01/16/2007 |
| 7157245 | Neisserial vaccine compositions and methods Methods and compositions for the treatment of microbial infection, and in particular meningococcal disease, comprise a commensal Neisseria or an extract of a commensal Neisseria. Further methods and compositions comprise commensal Neisseria whic... | 01/02/2007 |
| 7122197 | Compounds from The invention provides BASB020 polypeptides and polynucleotides encoding BASB020 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. ... | 10/17/2006 |
| 7118757 | Meningococcal class 1 outer-membrane protein vaccine Outer-membrane vesicles, Class 1 outer membrane proteins of Neisseria meningitidis, fragments or oligopeptides containing epitopes of the Class I OMP can be used to immunize against meningococcal disease. ... | 10/10/2006 |
| 7112332 | Oral or intranasal vaccines using hydrophobic complexes having proteosomes and lipopolysaccharides An immunogenic complex, essentially consisting of neisserial outer membrane protein proteosomes hydrophobically complexed to native purified bacterial lipopolysaccaride and formulated in accordance with the current invention for mucosal delivery such as via the oral... | 09/26/2006 |
